Preoperative staging of suspicious axillary lymph nodes (ALNs) allows patients to be triaged to ALN dissection or to sentinel lymph node biopsy (SLNB). Ultrasound-guided fine needle aspiration (FNA) and cytology of ALN is moderately sensitive but its clinical utility relies heavily on the cytologist’s experience. We proposed that the 5-h automated GeneXpert system-based prototype breast cancer detection assay (BCDA) that quantitatively measures DNA methylation in ten tumor-specific gene markers could provide a facile, accurate test for detecting cancer in FNA of enlarged lymph nodes. We validated the assay in ALN-FNA samples from a prospective study of patients (N = 230) undergoing SLNB. In a blinded analysis of 218 evaluable LN-FNAs from 108 malignant and 110 benign LNs by histology, BCDA displayed a sensitivity of 90.7% and specificity of 99.1%, achieving an area under the ROC curve, AUC of 0.958 (95% CI: 0.928–0.989; P < 0.0001). Next, we conducted a study of archival FNAs of ipsilateral palpable LNs (malignant, N = 72, benign, N = 53 by cytology) collected in the outpatient setting prior to neoadjuvant chemotherapy (NAC). Using the ROC-threshold determined in the prospective study, compared to cytology, BCDA achieved a sensitivity of 94.4% and a specificity of 92.5% with a ROC-AUC = 0.977 (95% CI: 0.953–1.000; P < 0.0001). Our study shows that the automated assay detects cancer in suspicious lymph nodes with a high level of accuracy within 5 h. This cancer detection assay, scalable for analysis to scores of LN FNAs, could assist in determining eligibility of patients to different treatment regimens.
A 9-year-old girl presented with a slow-growing and painless mass for 7 months in the soft tissue of the sacrococcygeal region. Magnetic resonance imaging revealed a well-circumscribed solid mass located in the subcutaneous soft tissue of the sacrococcygeal area, but not affecting bone structures. The mass was completely removed, and the disorder was diagnosed as myxopapillary ependymoma. In addition, the MYCN gene amplification status of the tumor was evaluated. Extra-axial ependymomas are very rare tumors with a tendency to metastasis, but they are usually regarded as low-grade ependymomas. Long-time surveillance and follow-up are necessary even after complete excision. Besides, we also discuss the diagnosis of primary soft tissue myxopapillary ependymoma.
Solitary fibrous tumor (SFT) is an uncommon fibroblastic neoplasm which may arise in a wide range of anatomic location and can occur across all ages. Fat-forming SFT is a rare morphological variant of SFT. Primary breast fat-forming SFT is exquisitely rare. Here, we report a case in a 51-year-old Chinese woman with a palpable painless mass in the left breast. A color Doppler ultrasound scan examination demonstrated a 3.4-cm oval, well-circumscribed, hypoechoic solid mass with several peripheral and internal color flow signals. Magnetic resonance imaging (MRI) showed a focal lobulated solid nodular lesion displaying geographical enhancement but no architectural distortion. Subsequently, she underwent a left breast lumpectomy. In histopathologic examination, there was a well-circumscribed, cellular spindle cell tumor consisting of short fascicles of bland, fusiform, ovoid to spindle cells disposed in a patternless architecture around branching vascular spaces within a fibrous stroma with wispy collagen. Cells revealed mild nuclear atypia. Mitotic figures were up to 4/10 high-power fields (HPFs) in the hot spot. Mature adipocytes intermixed with spindle cells were also observed. The tumor cells were diffusely positive for CD34 and STAT6. Some S100-expressing adipocytes co-expressed STAT6. Next-generation sequencing (NGS) revealed the presence of the NAB2exon6::STAT6exon2 fusion. The histological, immunohistochemical (IHC) and molecular examinations confirmed the diagnosis of fat-forming SFT. Post-excision, the patient showed no signs of tumor recurrence or metastasis in a 7-month follow-up. Here, we describe a rare case of a fat-forming SFT involving the breast and highlight the comprehensive pathological evaluation and necessary ancillary testing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.